This episode examines the operational deployment of AI in radiology, where one thousand four hundred and one FDA-cleared tools have produced workflow augmentation rather than job displacement. Pharmaceutical trial productivity gains are quantified through Novartis site selection compression and GSK cost reductions totaling eight million pounds on late-stage studies. Japan’s conditional approval pathway positions Amchepry and Reheart as the first iPSC-derived therapies to reach regulatory clearance, while Grail’s NHS-Galleri trial failure with one hundred forty-two thousand participants recalibrates validation standards for multicancer liquid biopsy platforms. Medtronic’s commercial launch of the Hugo robotic surgery system marks formal U.S. market entry in soft tissue procedures.
